

within two days prior to discharge from an inpatient facility to home.

3. The most recent arterial blood gas PO<sub>2</sub> and/or oxygen saturation test performed at rest, during exercise, or during sleep.

4. Name and address of the physician/provider performing the most recent arterial blood gas PO<sub>2</sub> and/or oxygen saturation test.

5. If ordering portable oxygen, information regarding the patient's mobility within the home.

6. Identification of the highest oxygen flow rate (in liters per minute) prescribed.

7. If the prescribed liters per minute (LPM), as identified in item 6, are greater than 4 LPM, provide the results and date of the most recent arterial blood gas PO<sub>2</sub> and/or oxygen saturation test taken on 4 LPM.

If the PO<sub>2</sub> = 56–59, or the oxygen saturation = 89%, then evidence of the beneficiary meeting at least one of the following criteria must be provided.

8. The patient having dependent edema due to congestive heart failure.

9. The patient having cor pulmonale or pulmonary hypertension, as documented by P pulmonale on an EKG or by an echocardiogram, gated blood pool scan or direct pulmonary artery pressure measurement.

10. The patient having a hematocrit greater than 56%.

Form HCFA-484 obtains all pertinent information and promotes national consistency in coverage determinations; *Frequency*: Other (as needed); *Affected Public*: Individuals/households, business or other for profit, and not for profit institutions; *Number of Respondents*: 300,000; *Total Annual Responses*: 300,000; *Total Annual Hours Requested*: 50,000.

To obtain copies of the supporting statement, and any related forms referenced above, E-mail your request, including your address and phone number, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786-1326. Written comments and recommendations for the proposed information collections must be mailed within 30 days of this notice directly to the OMB Desk Officer designated at the following address: OMB Human Resources and Housing Branch, Attention: Allison Eydt, New Executive Office Building, Room 10235, Washington, D.C. 20503.

Dated: December 2, 1997.

**John P. Burke III,**

*HCFA Reports Clearance Officer, HCFA, Office of Information Services, Information Technology Investment Management Group, Division of HCFA Enterprise Standards.*

[FR Doc. 97-32100 Filed 12-8-97; 8:45 am]

BILLING CODE 4120-03-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of National Cancer Institute Director's Consumer Liaison Group Meeting

Notice is hereby given that the National Cancer Institute will hold its first public meeting of the Director's Consumer Liaison Group, beginning at 9:00 a.m. on December 17, 1997 and ending at 3:00 p.m. on December 18, 1997 at the Pooks Hill Marriott, Bethesda, MD. Seating is limited and will be on a first-come, first-served basis.

The National Cancer Institute (NCI), the federal government's primary agency for cancer research, is bringing together fifteen (15) consumer-advocates to create a two-way street that enables them to interact directly with the scientific community at NCI on a wide range of programs and issues. The 15-member DCLG is made up of people involved in cancer advocacy and who reflect the breadth and diversity among those whose lives are touched by cancer. The DCLG will also help NCI to widen the pool of qualified consumer-advocates who can be called upon to serve on NCI advisory committees and other groups.

The members are (in alphabetical order):

Paula E. Bowen, Brooklyn, N.Y.  
Susan Lowell Butler, Alexandria, Va.  
Manuel H. Castillo, Dayton, Ohio  
Kerry J. Dewey, Missoula, Mont.  
M. Venus Gines, Lithonia, Ga.  
Felicia Schanche Hodge, Berkeley, Calif.  
Michael Katz, New York, N.Y.  
Susan A. Leigh, Tucson, Ariz.  
Ruth Chiang Lin, Short Hills, N.J.  
Gena H. Love, Albuquerque, N.M.  
Susan McCarthy, Vancouver, Wash.  
Daniel M. Moore, Jr., Decatur, Ill.  
Lillouise Rogers, Chicago, Ill.  
Susan K. Stewart, Highland Park, Ill.  
Brad Zebrack, Ann Arbor, Mich.

The majority of the newly appointed DCLG members are cancer survivors, but family members of cancer patients and health professionals involved in cancer advocacy are represented. The cancer experience of the group includes

prostate, breast, kidney, ovarian, cervical, lung, bladder, and brain cancer, Hodgkin's disease, leukemia, sarcoma, and myeloma. The group represents Asian American, Native American, Hispanic, African American, and non-Hispanic white persons, the young and old, men and women, the medically underserved, and people from all geographic areas of the country, both rural and urban. The constituencies represented by the members include advocacy organizations that represent both specific cancers and all cancers. DCLG members will serve three-year terms. The three-fold purpose of the DCLG will be to:

- Serve as a primary forum for discussing issues and concerns and exchanging viewpoints that are important to the broad development of NCI program and research priorities.
- Help develop and establish processes, mechanisms, and criteria for identifying appropriate consumer advocates to serve on a variety of NCI program and policy advisory committees.
- Establish and maintain strong collaborations between NCI and the cancer advocacy community.

One purpose of this first meeting is to decide how the group will do its work. For example, how it will select a chair and identify members who will serve in the future. The DCLG will also discuss how it will communicate internally and with the broad advocacy community it represents. In addition, the group will begin discussion on several key issues for the Institute. The most pressing issues faced by cancer patients today, as described in the candidates' applications, include: Access to and availability of reliable cancer information; access to effective, high-quality treatment, including clinical trials; increased rehabilitation, psychosocial support, and other survivor concerns; and participation in setting research priorities. NCI may also begin issues to the attention of the group.

Individuals who plan to attend the meeting and need special assistance, such as sign language interpretation or other special accommodations, should contact Elaine C. Lee, in the Office of Liaison Activities, National Cancer Institute, Building 31, Room 10A06; or by calling telephone No. 301 594-3194 or sending a fax to 301 480-7558. For additional information, contact Ms. Lee at the above address.

Dated: December 2, 1997.

**Marvin Kalt,**

*Director, Division of Extramural Activities,  
National Cancer Institute.*

[FR Doc. 97-32089 Filed 12-8-97; 8:45 am]

BILLING CODE 4140-01-M

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES**

**National Institutes of Health**

**National Cancer Institute; Notice of  
Closed Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Cancer Institute Special Emphasis Panel (SEP) meeting:

*Name of SEP: SBIR Phase I—Innovative Approaches to Clinical Trials 1 Informatics (Telephone Conference Call).*

*Date: December 15, 1997.*

*Time: 2:30 p.m. to Adjournment.*

*Place: National Cancer Institute, Executive Plaza North, Conference Room 640, 6130 Executive Boulevard, Bethesda, MD 20892.*

*Contact Person: Wilna Woods, Ph.D., Scientific Review Administrator, National Cancer Institute, NIH, Executive Plaza North, Room 622B, 6130 Executive Boulevard, MSC 7405, Bethesda, MD 20892-7405, Telephone: 301/496-7903.*

*Purpose/Agenda: To review, discuss and evaluate responses to Request for Proposal.*

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: December 2, 1997.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 97-32090 Filed 12-8-97; 8:45 am]

BILLING CODE 4140-01-M

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES**

**National Institutes of Health**

**National Institute of Allergy and  
Infectious Diseases; Notice of Closed  
Meeting**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Allergy and Infectious Diseases Special Emphasis Panel (SEP) meeting:

*Name of SEP: Unsolicited R01 (Telephone Conference Call).*

*Date: December 16, 1997.*

*Time: 12:00 p.m. to Adjournment.*

*Place: Teleconference, 6003 Executive Boulevard, Solar Building, Room 4C01, Bethesda, MD 20892, (301) 496-2550.*

*Contact Person: Dr. Dennis Lang, Scientific Review Adm., 6003 Executive Boulevard, Solar Bldg., Room 4C16, Bethesda, MD 20892, (301) 496-2550.*

*Purpose/Agenda: To evaluate a grant application.*

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Dated: December 2, 1997.

**LaVerne Y. Stringfield,**

*Committee Management Officer, NIH.*

[FR Doc. 97-32087 Filed 12-8-97; 8:45 am]

BILLING CODE 4140-01-M

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES**

**National Institutes of Health**

**National Institute on Drug Abuse;  
Notice of Closed Meetings**

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute on Drug Abuse (NIDA) Special Emphasis Panel meetings.

*Purpose/Agenda: To review and evaluate grant applications and contract proposals.*

*Name of Committee: NIDA Special Emphasis Panel (Contract Review—"Internet-Based Research Support for Drug Abuse Researchers").*

*Date: December 10, 1997.*

*Time: 9:00 a.m.*

*Place: Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, MD 20814.*

*Contact Person: Mr. Lyle Furr, Contract Review Specialist, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10-42, Rockville, MD 20857, Telephone (301) 443-1644.*

*Name of Committee: NIDA Special Emphasis Panel (Contract Review—"Development of a Computerized Neuropsychological Testing Programs").*

*Date: December 17, 1997.*

*Time: 9:00 a.m.*

*Place: Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, MD 20814.*

*Contact Person: Mr. Lyle Furr, Contract Review Specialist, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10-42, Rockville, MD 20857, Telephone (301) 443-1644.*

*Name of Committee: NIDA Special Emphasis Panel (Contract Review—"Analytical Techniques Programs").*

*Date: December 19, 1997.*

*Time: 11:30 a.m.*

*Place: National Institute on Drug Abuse, NIH, 5600 Fishers Lane, Room 10-49, Rockville, MD 20857.*

*Contact Person: Mr. Eric Zatman, Contract Review Specialist, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10-42, Rockville, MD 20857, Telephone (301) 443-1644.*

This notice is being published less than 15 days prior to the meetings due to the urgent need to meet timing limitations imposed by the review and funding cycle.

*Name of Committee: NIDA Special Emphasis Panel (Contract Review—"Development Research Dissemination").*

*Date: January 7, 1998.*

*Time: 9:00 a.m.*

*Place: Bethesda Marriott Hotel, 5151 Pooks Hill Road, Bethesda, MD 20814.*

*Contact Person: Mr. Lyle Furr, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10-42, Rockville, MD 20857, Telephone (301) 443-1644.*

*Name of Committee: NIDA Special Emphasis Panel (Conference Grants).*

*Date: January 8, 1998.*

*Time: 9:00 a.m.*

*Place: National Institute on Drug Abuse, NIH, NIDA Conference Room 10-05, 5600 Fishers Lane, Rockville, MD 20857.*

*Contact Person: Dr. William C. Grace, Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10-42, Rockville, MD 20857, Telephone (301) 443-2755.*

The meetings will be closed in accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the